Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

MLA

Pernicova, Ida, et al. “Metformin to Reduce Metabolic Complications and Inflammation in Patients on Systemic Glucocorticoid Therapy: A Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Trial.” The Lancet. Diabetes & Endocrinology, vol. 8, no. 4, Apr. 2020, pp. 278–91. EBSCOhost, https://doi.org/10.1016/S2213-8587(20)30021-8.

APA

Pernicova, I., Kelly, S., Ajodha, S., Sahdev, A., Bestwick, J. P., Gabrovska, P., Akanle, O., Ajjan, R., Kola, B., Stadler, M., Fraser, W., Christ-Crain, M., Grossman, A. B., Pitzalis, C., & Korbonits, M. (2020). Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. The Lancet. Diabetes & Endocrinology, 8(4), 278–291. https://doi.org/10.1016/S2213-8587(20)30021-8

Chicago

Pernicova, Ida, Stephen Kelly, Sharon Ajodha, Anju Sahdev, Jonathan P Bestwick, Plamena Gabrovska, Olufunso Akanle, et al. 2020. “Metformin to Reduce Metabolic Complications and Inflammation in Patients on Systemic Glucocorticoid Therapy: A Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Trial.” The Lancet. Diabetes & Endocrinology 8 (4): 278–91. doi:10.1016/S2213-8587(20)30021-8.